You searched for cellectis - Page 2 of 12

News and Trends 29 Jul 2015

Erytech follows the path of DBV and Cellectis into the US stock exchange

Erytech Pharma, developer of an innovative ‘tumor starvation’ treatment, today announced that it plans to conduct a registered initial public offering in the United States and thus, plays in the major league with its French fellows DBV and Cellectis. It’s definitely the last trend in Biotech! European companies are queuing up to enter the US stock market. In […]

July 29, 2015 - 2 minutesmins - By Joachim Eeckhout

News and Trends 15 Jul 2015

How Servier saved Cellectis, the French CAR-T Miracle

Cellectis, the €1bn CAR-T company, just announced it reached a significant milestone in its collaboration with Servier. Surprisingly, early 2014, Cellectis and its 300 employees were only three months away from bankruptcy, mainly because of the competing gene-editing technology CRISPR. How and why did Servier save them? Let’s find out. Cellectis was founded in 1999 in Paris and […]

July 15, 2015 - 5 minutesmins - By Philip Hemme

News and Trends 29 May 2015

Pfizer to Control Cellectis in a €1.5 Billion Deal?

Rumors are saying that French Cellectis is in talks about its potential sale. US-giant Pfizer is considered to be among the buyers. According to The Financial Time, two people familiar with the situation said Cellectis was in negotiations over a deal, but warned no outcome was certain. The Financial Time also declared that “one person […]

May 29, 2015 - 2 minutesmins - By Joachim Eeckhout

News and Trends 26 Mar 2015

With €200 Million, Cellectis is on its way to make the Biggest French Biotech IPO ever

Exactly one month ago, the article “Cellectis is preparing its IPO in the U.S” explained Cellectis prepared an IPO to be listed on the NASDAQ. Yesterday, the company announced the pricing of its initial public offering. Its goal is to raise €197M and up to €226.8M in case of allotment. A large amount of ressources […]

March 26, 2015 - 2 minutesmins - By Joachim Eeckhout

News and Trends 25 Feb 2015

Cellectis is preparing its IPO in the U.S

Cellectis is a company focused on developing immunotherapies based on gene edited engineered CAR-T cells. The company’s mission is to develop a new generation of cancer therapies based on engineered T-cells. With 15 years of expertise, Cellectis is already listed on the NYSE Alternext market (ticker: ALCLS) and now preparing its IPO to be listed on the […]

February 25, 2015 - 2 minutesmins - By Joachim Eeckhout

In Depth 11 Mar 2024

Biotech bankruptcies: what to expect in 2024 following a record year?

2023 broke the record for the highest number of biotech bankruptcies in a decade. Can biotechs mitigate the risk in 2024?

March 11, 2024 - 7 minutesmins - By Roohi Mariam Peter

Weekly Roundup 10 Nov 2023

Korro Bio and Frequency’s merger; Lexeo’s $100 million IPO; Gate Biosciences new class of drugs

You are reading Labiotech’s weekly roundup of the latest biotech news. Korro Bio and Frequency Therapeutics close merger Last Friday, Korro Bio announced the completion of the previously announced business combination between Frequency Therapeutics, Inc. and the entity formerly known as Korro Bio. The combined company will now operate under the name Korro Bio, Inc. […]

November 10, 2023 - 12 minutesmins - By Willow Shah-Neville

Best in Biotech 4 Nov 2022

Get to know 15 of the best biotech companies in Paris

Paris may attract tourist masses, but it also attracts a lot of biotech enthusiasts. In this guide, we explore 15 interesting biotech companies in Paris. Paris is one of the biggest biotech clusters in Europe, with a wide range of applications being developed from drug discovery and medical devices to synthetic biology and green energy. […]

November 4, 2022 - 11 minutesmins - By Omnia Ibrahim

News and Trends 19 Jul 2022

eureKARE launches synthetic biology studio network

eureKARE, a company focused on financing and building next generation biotech companies in the fields of synthetic biology, has launched its first synthetic biology studio in Belgium. In conjunction with this, eureKARE has appointed Georges Rawadi as chief of biotech studio development. eureKARE said its thematic synthetic biology studio model is a novel, flexible approach […]

July 19, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 1 Jul 2022

Beyond Biotech podcast 3: Ariceum Therapeutics, TWB, Unilever

On this week’s podcast, we have three conversations: with Manfred Rüdiger, CEO of Ariceum Therapeutics; Jon Hague, Unilever’s R&D VP for homecare; and Olivier Rolland, executive director at TWB. Ambrosia and Dionymer winners at 2022 TWB Start-Up Day TWB, which sets up industrial biotechnology R&D projects and designer of innovative and sustainable solutions, announces the […]

July 1, 2022 - 9 minutesmins - By Jim Cornall

Paris France biotech healthcare life sciences

In Depth 20 Jun 2022

France’s grand plan to lead Europe’s biotech innovation landscape

For decades, the French biotech scene has been catching up to key strongholds such as the U.S. and U.K. In the aftermath of the COVID-19 pandemic, the French government last year bet €7.5 billion on an ambitious project to turn France into Europe’s health innovation magnet by 2030. France is one of Europe’s most established […]

June 20, 2022 - 7 minutesmins - By Jonathan Smith

News and Trends 16 May 2022

Valneva’s Covid-19 Vaccine Contract in Dire Straits as EU Approval Lags

The stock price of the French Covid-19 vaccine maker Valneva has been knocked down by 20% as the company faces losing a supply contract with the European Commission. Despite receiving a glowing marketing authorization from the UK’s drug regulator in April this year, Valneva is struggling to gain traction with its Covid-19 vaccine in the […]

May 16, 2022 - 3 minutesmins - By Jonathan Smith

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Search Results for: cellectis

Erytech follows the path of DBV and Cellectis into the US stock exchange

How Servier saved Cellectis, the French CAR-T Miracle

Pfizer to Control Cellectis in a €1.5 Billion Deal?

With €200 Million, Cellectis is on its way to make the Biggest French Biotech IPO ever

Cellectis is preparing its IPO in the U.S

Biotech bankruptcies: what to expect in 2024 following a record year?

Korro Bio and Frequency’s merger; Lexeo’s $100 million IPO; Gate Biosciences new class of drugs

Get to know 15 of the best biotech companies in Paris

eureKARE launches synthetic biology studio network

Beyond Biotech podcast 3: Ariceum Therapeutics, TWB, Unilever

France’s grand plan to lead Europe’s biotech innovation landscape

Valneva’s Covid-19 Vaccine Contract in Dire Straits as EU Approval Lags

Subscribe to our newsletter to get the latest biotech news!